Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine

Journal of Clinical Oncology

Volumn 28, Issue 25, 2010, Pages 3922-3928

  Cortes, Javier ^a   Vahdat, Linda ^a   Blum, Joanne L ^a   Twelves, Chris ^a   Campone, Mario ^a   Roché, Henri ^a   Bachelot, Thomas ^a   Awada, Ahmad ^a   Paridaens, Robert ^a   Goncalves, Anthony ^a   Shuster, Dale E ^a   Wanders, Jantien ^a   Fang, Fang ^a   Gurnani, Renuka ^a   Richmond, Elaine ^a   Cole, Patricia E ^a   Ashworth, Simon ^a   Allison, Mary Ann ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTHRAQUINONE; ANTIBIOTIC AGENT; ANTIEMETIC AGENT; ANTIHISTAMINIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CAPECITABINE; CARBOPLATIN; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; ERIBULIN; FLUOROURACIL; GEMCITABINE; GROWTH FACTOR; METHOTREXATE; NAVELBINE; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; TAXANE DERIVATIVE; TRASTUZUMAB; 2 (3 AMINO 2 HYDROXYPROPYL)HEXACOSAHYDRO 3 METHOXY 26 METHYL 20,27 BIS(METHYLENE)11,15 18,21 24,28 TRIEPOXY 7,9 ETHANO 12,15 METHANO 9H,15H FURO(3,2 I)FURO(2',3' 5,6)PYRANO(4,3 B)(1,4)DIOXACYCLOPENTACOSIN 5 (4H) ONE; 2-(3-AMINO-2-HYDROXYPROPYL)HEXACOSAHYDRO-3-METHOXY-26-METHYL-20,27-BIS(METHYLENE)11,15-18,21-24,28-TRIEPOXY-7,9-ETHANO-12,15-METHANO-9H,15H-FURO(3,2-I)FURO(2',3'-5,6)PYRANO(4,3-B)(1,4)DIOXACYCLOPENTACOSIN-5-(4H)-ONE; ANTINEOPLASTIC AGENT; ETHER DERIVATIVE; FURAN DERIVATIVE; HALICHONDRIN B; KETONE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ANTIBIOTIC THERAPY; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; ASTHENIA; BREAST CANCER; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ASSESSMENT; CONSTIPATION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HUMAN; INFECTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MOTOR NEUROPATHY; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SENSORY NEUROPATHY; STOMATITIS; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; MIDDLE AGED; PATHOLOGY; RETREATMENT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; ETHERS, CYCLIC; FEMALE; FURANS; HUMANS; KETONES; MIDDLE AGED; PERIPHERAL NERVOUS SYSTEM DISEASES; RETREATMENT;

EID: 77957594393     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.25.8467     Document Type: Article

References (16)

1. Garcia M, Jemal A, Ward EM, et al: Global cancer facts and figures 2007. http://www.cancer .org/downloads/STT/Global-Facts-and-Figures-2007-rev2.pdf
2. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology V. 1.2010. http://www.nccn.org/professionals/physician-gls/PDF/ breast.pdf
3. Colozza M, de Azambuja E, Personeni N, et al: Achievements in systemic therapies in the pregenomic era in metastatic breast cancer. Oncologist 12:253-270, 2007 (Pubitemid 46556792)
4. Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN: Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 608:1-22, 2007
5. Jordan MA, Kamath K, Manna T, et al: The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther 4:1086-1095, 2005 (Pubitemid 41079102)
6. Kuznetsov G, Towle MJ, Cheng H, et al: Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389. Cancer Res 64:5760-5766, 2004 (Pubitemid 39095575)
7. Okouneva T, Azarenko O, Wilson L, et al: Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase. Mol Cancer Ther 7:2003-2011, 2008
8. Towle MJ, Salvato KA, Budrow J, et al: In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res 61:1013-1021, 2001
9. Kuznetsov G, TenDyke K, Yu MJ, et al: Anti-proliferative effects of halichondrin B analog eribulin mesylate (E7389) against paclitaxel-resistant human cancer cells in vitro. Proc Am Assoc Cancer Res 48:275, 2007 (abstr C58)
10. Vahdat LT, Pruitt B, Fabian CJ, et al: Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 27:2954-2961, 2009
11. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
12. Wolf S, Barton D, Kottschade L, et al: Chemotherapy-induced peripheral neuropathy: Prevention and treatment strategies. Eur J Cancer 44:1507-1515, 2008
13. Mayer EL, Burstein HJ: Chemotherapy for metastatic breast cancer. Hematol Oncol Clin North Am 21:257-272, 2007 (Pubitemid 46754731)
14. Hausheer FH, Schilsky RL, Bain S, et al: Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol 33:15-49, 2006 (Pubitemid 43214485)
15. Perez EA, Lerzo G, Pivot X, et al: Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol 25:3407-3414, 2007 (Pubitemid 47310876)
16. Eisai Company: Global phase III study results show eribulin meets primary endpoint of overall survival, 09 update. http://www.eisai.co.jp/enews/ enews200946.html